测量循环肿瘤细胞的血液测试预测了转移性前列腺癌病人的存活和治疗反应。 Blood test measuring circulating tumor cells predicts survival and treatment response in metastatic prostate cancer patients.

测量循环肿瘤细胞(CTCs)的新血液测试可以预测前列腺转移癌患者的存活和治疗反应。 A new blood test measuring circulating tumor cells (CTCs) may predict survival and treatment response in patients with metastatic prostate cancer. 一项3期试验发现,较高的CTC计数与较短的生存期和死亡风险增加有关. A phase 3 trial found that higher CTC counts correlate with shorter survival and increased mortality risk. 这一测试可以指导医生将治疗计划个性化,确定可能受益于更积极治疗或临床试验的病人。 This test could guide doctors in personalizing treatment plans, identifying patients who may benefit from more aggressive therapies or clinical trials. 该研究报告在国家癌症研究所资助下,在JAMA网络公开发表。 The study was published in JAMA Network Open and funded by the National Cancer Institute.